...
首页> 外文期刊>Journal of interventional cardiac electrophysiology: an international journal of arrhythmias and pacing >Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial (PAUSE-SCD): rationale and study design
【24h】

Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial (PAUSE-SCD): rationale and study design

机译:泛亚美国预防心脏病死亡导管烧蚀试验(暂停SCD):理由和研究设计

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background The role of catheter ablation as an adjunct and alternative to ICD implantation is not known in patients at risk for recurrent ventricular tachycardia (VT) and sudden cardiac death (SCD) across Asia. Patients with nonischemic etiologies of cardiomyopathy, which are highly prevalent in Asia, have not been previously enrolled in randomized trials of VT ablation. Objective To evaluate whether preemptive catheter ablation in patients with monomorphic VT and an indication for ICD implantation results in improved clinical outcomes compared to ICD implantation with standard medical therapy alone. To examine the natural history of ablation outcomes in the absence of background ICD therapy in patients that refuse randomization. Methods The PAUSE-SCD study (NCT02848781) is a prospective, multi-center, randomized controlled trial enrolling patients with structural heart disease (EF < 50%) with an indication for ICD implantation. Patients are randomized in a 1:1 fashion to two treatment arms: ICD with ablation and ICD with standard medical therapy alone. A prospective registry cohort was designed to follow the outcomes of patients who refuse ICD and randomization but elect to receive catheter ablation as primary therapy. The primary endpoint is defined as a composite of recurrent VT, cardiovascular rehospitalization, and death. Pre-specified secondary endpoints include each of the individual components of the primary endpoint in addition to comparison between randomized and registry patients. Conclusion The PAUSE-SCD study is a prospective, multi-center, randomized, and controlled trial examining the impact of preemptive catheter ablation on cardiovascular outcomes in patients with an indication for ICD at risk for recurrent VT and SCD. It represents the first multi-center VT ablation study in Asia, with a design intended to provide insights into the role of both ICD and ablation therapy in a predominantly nonischemic population.
机译:背景技术导管消融作为辅助植入的辅助作用和替代ICD植入的替代性在亚洲患有经常性室性心动过速(VT)和突然心脏死亡(SCD)的风险中未知。亚洲普遍普遍存在的心肌病的患者患者以前尚未参加VT消融的随机试验。目的探讨患有单数vt患者的先发药导管消融和ICD植入的指示导致与ICD植入单独使用标准的医疗疗法相比改善临床结果。在拒绝随机化的患者的情况下,检查缺乏背景ICD治疗的消融结果的自然历史。方法暂停SCD研究(NCT02848781)是一种前瞻性多中心随机对照试验,患有结构性心脏病(EF <50%)的患者,具有ICD植入的指示。患者在1:1时装中随机分为两种治疗臂:ICD与单独的标准医疗疗法融合和ICD。旨在遵守拒绝ICD和随机化的患者的结果,旨在遵循患者的结果,而是选择接受导管消融作为主要疗法。主要终点被定义为复发性VT,心血管再生生长和死亡的复合物。预先指定的辅助端点包括除了随机和注册患者之间的比较之外,还包括主要端点的每个各个组件。结论暂停SCD研究是一种前瞻性,多中心,随机,随机和对照试验,检查先发制的导管消融对患者心血管结果的影响,患者患有反复性VT和SCD的风险。它代表了亚洲的第一个多中心VT消融研究,其中设计旨在为ICD和消融治疗的角色提供洞察力,主要是缺乏缺乏症群体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号